(Total Views: 887)
Posted On: 08/25/2017 9:15:06 AM
Post# of 72446
What's wrong with this picture? Market caps for some small or development-stage biotechs:
AVXL 191 Million
One drug in a small clinical trial for Alzheimers, will take 2 years according to company.
ARTH 118 Million
1 technology -- wound sealant. Making good progress and I have some shares -- am bullish on the company, but, ONE technology.
AXON 2.1 Billion
Re-testing previously failed Alzheimer's drug which they purchased for 5 million from a big pharma that shelved it. IPO by Wall Street insiders and pumped by Cramer.
IPIX 99 Million
3 different drugs, 5 successful clinical trials for various applications
You can see that by these comparisons, we should have at least as high a market cap as AVXL. And, given that we have 3 times the drugs, really we should be at a minimum of 3 times the market cap of AVXL or at least ARTH.
To my mind, ARTH is really the comparison. They're making their way toward FDA approval of their product. We have 3 different drugs with 5 different applications (so far). Let's say that only 4 of those applications are ultimately successful -- let's build in an allowance for failure of one of them.
That would still leave us with 4 times ARTH's market cap of 118 million. Let's round it down to 400 million -- so, 4 times the current price of about .73 would value us at the same value the market assigns a one-trick pony.
That means about 2.90 right now would value IPIX comparably -- not even taking into account that IPIX's drugs have a VASTLY larger market than ARTH's stuff has.
AVXL 191 Million
One drug in a small clinical trial for Alzheimers, will take 2 years according to company.
ARTH 118 Million
1 technology -- wound sealant. Making good progress and I have some shares -- am bullish on the company, but, ONE technology.
AXON 2.1 Billion
Re-testing previously failed Alzheimer's drug which they purchased for 5 million from a big pharma that shelved it. IPO by Wall Street insiders and pumped by Cramer.
IPIX 99 Million
3 different drugs, 5 successful clinical trials for various applications
You can see that by these comparisons, we should have at least as high a market cap as AVXL. And, given that we have 3 times the drugs, really we should be at a minimum of 3 times the market cap of AVXL or at least ARTH.
To my mind, ARTH is really the comparison. They're making their way toward FDA approval of their product. We have 3 different drugs with 5 different applications (so far). Let's say that only 4 of those applications are ultimately successful -- let's build in an allowance for failure of one of them.
That would still leave us with 4 times ARTH's market cap of 118 million. Let's round it down to 400 million -- so, 4 times the current price of about .73 would value us at the same value the market assigns a one-trick pony.
That means about 2.90 right now would value IPIX comparably -- not even taking into account that IPIX's drugs have a VASTLY larger market than ARTH's stuff has.
(4)
(0)
